SABRINA LYDON: Open Payments
NPI 1275316226 · KILLEEN, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$974 in 37 payments from 9 companies in 2025. Trend: 2023 $0 · 2024 $937 · 2025 $974
Food & beverage: $967Education: $8
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 4 | $269 |
| Tempus AI, Inc | 10 | $200 |
| Supernus Pharmaceuticals, Inc. | 8 | $190 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $95 |
| ABBVIE INC. | 3 | $70 |
| Axsome Therapeutics, Inc. | 3 | $54 |
| Neurocrine BioSciences, Inc. | 2 | $41 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $38 |
| Paratek Pharmaceuticals, Inc. | 1 | $18 |
Products named: COBENFY, TEMPUS PIXEL, Qelbree, CAPLYTA, VRAYLAR, Auvelity, INGREZZA, TRINTELLIX.
Industry payments across TX — which companies pay providers there.
